Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Article Oncology

Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Nobuaki Matsubara et al.

Summary: Enfortumab vedotin has shown significant overall survival benefit for patients with advanced urothelial carcinoma, including in the Japanese population. It has consistent efficacy and safety, making it an important treatment option for previously treated patients with this condition.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Vadim S. Koshkin et al.

Summary: Enfortumab vedotin has shown consistent responses in a large retrospective cohort, including patients with variant histology, FGFR3 alterations, and previously excluded patients with comorbidities and low estimated glomerular filtration rates. The drug has been effective in treating a wide range of patient populations, replicating previously reported clinical trial data in a real-world setting.

CANCER (2022)

添加到收藏夹

Article Urology & Nephrology

Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study

Takashi Kawahara et al.

Summary: This study investigated the effect of Ra-223 as a life-prolonging agent in a large Japanese healthcare fee database. The results showed that bone metastatic CRPC patients who received Ra-223 had a significantly better prognosis than those who did not receive Ra-223.

INTERNATIONAL JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Oncology

Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada

Nimira Alimohamed et al.

Summary: Real-world data on treatment patterns and survival outcomes of patients with unresectable locally advanced or metastatic urothelial carcinoma (la/mUC) in Canada are limited. This study found that the majority of patients did not receive systemic therapy, and those who did had poor survival outcomes. The results highlight the significant unmet need for safe and efficacious therapies for la/mUC patients in Canada.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Enfortumab vedotin - next game-changer in urothelial cancer

Moritz Maas et al.

Summary: Enfortumab vedotin has shown promising efficacy and good tolerability in phase I/II trials, particularly in heavily treated patients and those with liver metastases. It seems to be more effective than third-line chemotherapies, with ongoing studies to determine its potential in treatment sequences.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles et al.

Summary: Enfortumab vedotin significantly prolonged survival compared with standard chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor, as well as showing better progression-free survival outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial

Evan Y. Yu et al.

Summary: Enfortumab vedotin showed promising efficacy in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors, providing a new treatment option for a patient population with a high unmet need.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal